Insulin Resistance

What Is Insulin Resistance

Insulin resistance is a condition where cells throughout the body stop responding properly to insulin, causing blood sugar to rise, energy to crash after meals, and weight to accumulate especially around the midsection. Clinically, it involves impaired cellular insulin signaling characterized by reduced glucose transporter translocation, compensatory hyperinsulinemia, and progressive metabolic dysfunction that may drive type 2 diabetes, dyslipidemia, and visceral adiposity.

The early signs are often subtle and easily overlooked. Afternoon energy crashes, persistent hunger shortly after eating, stubborn midsection weight gain, and fasting blood sugar readings that creep upward year after year are all hallmarks. Many people live with insulin resistance for a decade or more before receiving a formal diagnosis of prediabetes or type 2 diabetes. The condition is estimated to affect one in three adults, making it one of the most prevalent — and underdiagnosed — metabolic disorders.

Why Conventional Approaches Fall Short

Metformin remains the standard first-line therapy for insulin resistance and is effective at improving glucose control. However, it causes gastrointestinal side effects in a significant proportion of patients, produces only modest effects on body weight, and does not address the incretin deficiency component of insulin resistance. For patients whose metabolic dysfunction involves substantial visceral adiposity, appetite dysregulation, and progressive weight gain, metformin alone often cannot produce the degree of metabolic improvement needed to meaningfully reverse the condition. The gap between what metformin addresses — hepatic glucose output and peripheral insulin sensitivity — and the full scope of metabolic dysfunction in insulin resistance leaves room for more comprehensive approaches.

How Peptides Address Insulin Resistance

Semaglutide, a GLP-1 receptor agonist, enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central satiety signaling, improving insulin sensitivity through both weight loss and direct metabolic effects. Semaglutide has been demonstrated in human clinical trials to produce significant reductions in HbA1c and body weight, representing some of the most compelling results in metabolic medicine. It targets the root cause of insulin resistance through multiple complementary mechanisms.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, similarly improves insulin sensitivity through complementary incretin pathways. Also demonstrated in human clinical trials, tirzepatide has produced significant reductions in HbA1c and body weight, addressing insulin resistance at its root through a dual-receptor approach that may offer advantages over single-incretin therapies.

MOTS-c provides an adjunctive strategy by activating AMPK signaling to improve skeletal muscle glucose uptake and mitochondrial fatty acid oxidation, addressing insulin resistance at the cellular energy metabolism level. Studied in animal and in vitro models, MOTS-c targets a pathway independent of incretin signaling, potentially complementing GLP-1-based therapies by improving the cellular machinery of glucose disposal directly.

What to Monitor

Fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance) are the most direct measures of insulin sensitivity and should be tracked over time to assess metabolic trajectory. HbA1c provides a three-month average of blood sugar control, while fasting glucose captures the snapshot. Triglyceride levels often reflect the lipid dysregulation driven by hyperinsulinemia and tend to improve as insulin sensitivity recovers.

These biomarkers connect to the metabolic roots of the condition: impaired GLUT4 translocation that reduces cellular glucose uptake, chronic hyperinsulinemia that drives fat storage and inflammation, and visceral adipose tissue inflammation that perpetuates the cycle of resistance.

How This Relates to Your Health

Insulin resistance sits at the intersection of multiple chronic conditions. It is a primary driver of type 2 diabetes, contributes to obesity and visceral fat accumulation, and shares metabolic pathways with cardiovascular disease, non-alcoholic fatty liver disease, and certain cancers. Addressing insulin resistance early — before it progresses to frank diabetes — may reduce risk across this entire spectrum of metabolic disease, making it one of the highest-leverage targets in preventive health.